Chen, C. D. et al. Molecular determinants of resistance to antiandrogen remedy. Nat. Med. 10, 33–39 (2004).
Polkinghorn, W. R. et al. Androgen receptor signaling regulates DNA restore in prostate cancers. Most cancers Discov. 3, 1245–1253 (2013).
Chang, Ok.-H. et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate most cancers. Proc. Natl Acad. Sci. USA 108, 13728–13733 (2011).
Grasso, C. S. et al. The mutational panorama of deadly castration-resistant prostate most cancers. Nature 487, 239–243 (2012).
Scher, H. I. et al. Elevated survival with enzalutamide in prostate most cancers after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).
Chang, Ok.-H. et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate most cancers. Cell 154, 1074–1084 (2013).
Hussain, M. et al. Enzalutamide in males with nonmetastatic, castration-resistant prostate most cancers. N. Engl. J. Med. 378, 2465–2474 (2018).
Davis, I. D. et al. Enzalutamide with normal first-line remedy in metastatic prostate most cancers. N. Engl. J. Med. 381, 121–131 (2019).
Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate most cancers. Nat. Med. 22, 298–305 (2016).
Beltran, H. et al. Molecular characterization of neuroendocrine prostate most cancers and identification of latest drug targets. Most cancers Discov. 1, 487–495 (2011).
Aggarwal, R. et al. Scientific and genomic characterization of treatment-emergent small-cell neuroendocrine prostate most cancers: a multi-institutional potential examine. J. Clin. Oncol. 36, 2492–2503 (2018).
Dardenne, E. et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate most cancers. Most cancers Cell 30, 563–577 (2016).
Bluemn, E. G. et al. Androgen receptor pathway-independent prostate most cancers is sustained by FGF signaling. Most cancers Cell 32, 474–489.e476 (2017).
Yamada, Y. & Beltran, H. Scientific and organic options of neuroendocrine prostate most cancers. Curr. Oncol. Rep. 23, 15 (2021).
Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in sufferers with high-risk prostate most cancers earlier than curative-intent surgical procedure or radiotherapy (proPSMA): a potential, randomised, multicentre examine. Lancet 395, 1208–1216 (2020).
Hofman, M. S. et al. [177Lu]-PSMA-617 radionuclide therapy in sufferers with metastatic castration-resistant prostate most cancers (LuPSMA trial): a single-centre, single-arm, part 2 examine. Lancet Oncol. 19, 825–833 (2018).
Hofman, M. S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in sufferers with metastatic castration-resistant prostate most cancers (TheraP): a randomised, open-label, part 2 trial. Lancet 397, 797–804 (2021).
Sartor, O. et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate most cancers. N. Engl. J. Med. 385, 1091–1103 (2021).
Buteau, J. P. et al. PSMA and FDG-PET as predictive and prognostic biomarkers in sufferers given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate most cancers (TheraP): a biomarker evaluation from a randomised, open-label, part 2 trial. Lancet Oncol. 23, 1389–1397 (2022).
Chow, Ok. M. et al. Head-to-head comparability of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and traditional imaging modalities for preliminary staging of intermediate- to high-risk prostate most cancers: a scientific assessment and meta-analysis. Eur. Urol. 84, 36–48 (2023).
Pienta, Ok. J. et al. A part 2/3 potential multicenter examine of the diagnostic accuracy of prostate particular membrane antigen PET/CT with 18F-DCFPyL in prostate most cancers sufferers (OSPREY). J. Urol. 206, 52–61 (2021).
Perera, M. et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in superior prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a scientific assessment and meta-analysis. Eur. Urol. 77, 403–417 (2020).
Maurer, T., Eiber, M., Schwaiger, M. & Gschwend, J. E. Present use of PSMA–PET in prostate most cancers administration. Nat. Rev. Urol. 13, 226–235 (2016).
Sartor, O. et al. LBA13 part III trial of [177Lu]Lu-PSMA-617 in taxane-naive sufferers with metastatic castration-resistant prostate most cancers (PSMAfore). Ann. Oncol. 34, S1324–S1325 (2023).
Bakht, M. Ok. et al. Neuroendocrine differentiation of prostate most cancers results in PSMA suppression. Endocr. Relat. Most cancers 26, 131–146 (2019).
Bakht, M. Ok. et al. Differential expression of glucose transporters and hexokinases in prostate most cancers with a neuroendocrine gene signature: a mechanistic perspective for 18F-FDG imaging of PSMA-suppressed tumors. J. Nucl. Med. 61, 904–910 (2020).
Bakht, M. Ok. et al. Panorama of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate most cancers. Nat. Most cancers 4, 699–715 (2023).
Sayar, E. et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in superior metastatic prostate most cancers. JCI Perception 8, e162907 (2023).
Robinson, D. et al. Integrative medical genomics of superior prostate most cancers. Cell 161, 1215–1228 (2015).
Pritchard, C. C. et al. Inherited DNA-repair gene mutations in males with metastatic prostate most cancers. N. Engl. J. Med. 375, 443–453 (2016).
Silver, D. A., Pellicer, I., Honest, W. R., Heston, W. D. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in regular and malignant human tissues. Clin. Most cancers Res. 3, 81–85 (1997).
Wright, G. L., Haley, C., Beckett, M. L. & Schellhammer, P. F. Expression of prostate-specific membrane antigen in regular, benign, and malignant prostate tissues. Urol. Oncol. 1, 18–28 (1995).
Rahn, Ok. A., Slusher, B. S. & Kaplin, A. I. Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition. Curr. Med. Chem. 19, 1335–1345 (2012).
Rahn, Ok. A. et al. Inhibition of glutamate carboxypeptidase II (GCPII) exercise as a therapy for cognitive impairment in a number of sclerosis. Proc. Natl Acad. Sci. USA 109, 20101–20106 (2012).
Davis, M. I., Bennett, M. J., Thomas, L. M. & Bjorkman, P. J. Crystal construction of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl Acad. Sci. USA 102, 5981–5986 (2005).
Schülke, N. et al. The homodimer of prostate-specific membrane antigen is a practical goal for most cancers remedy. Proc. Natl Acad. Sci. USA 100, 12590–12595 (2003).
Rawlings, N. D. & Barrett, A. J. Construction of membrane glutamate carboxypeptidase. Biochim. Biophys. Acta 1339, 247–252 (1997).
Bernstein, L. H., Gutstein, S., Weiner, S. & Efron, G. The absorption and malabsorption of folic acid and its polyglutamates. Am. J. Med. 48, 570–579 (1970).
Zhao, R., Diop-Bove, N., Visentin, M. & Goldman, I. D. Mechanisms of membrane transport of folates into cells and throughout epithelia. Annu. Rev. Nutr. 31, 177–201 (2011).
Figueiredo, J. C. et al. Folic acid and danger of prostate most cancers: outcomes from a randomized medical trial. J. Natl Most cancers Inst. 101, 432–435 (2009).
Sanderson, S. M., Gao, X., Dai, Z. & Locasale, J. W. Methionine metabolism in well being and most cancers: a nexus of weight loss plan and precision drugs. Nat. Rev. Most cancers 19, 625–637 (2019).
Yao, V. & Bacich, D. J. Prostate particular membrane antigen (PSMA) expression provides prostate most cancers cells a progress benefit in a physiologically related folate atmosphere in vitro. Prostate 66, 867–875 (2006).
Reina-Campos, M. et al. Elevated serine and one-carbon pathway metabolism by PKCλ/ι deficiency promotes neuroendocrine prostate most cancers. Most cancers Cell 35, 385–400.e389 (2019).
Kaittanis, C. et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling by metabotropic glutamate receptors. J. Exp. Med. 215, 159–175 (2018).
Palamiuc, L. & Emerling, B. M. PSMA brings new flavors to PI3K signaling: a job for glutamate in prostate most cancers. J. Exp. Med. 215, 17–19 (2018).
Bakht, M. Ok. et al. Identification of other protein targets of glutamate-ureido-lysine related to PSMA tracer uptake in prostate most cancers cells. Proc. Natl Acad. Sci. USA 119, e2025710119 (2022).
Uhlén, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
Barron, D. A. & Rowley, D. R. The reactive stroma microenvironment and prostate most cancers development. Endocr. Relat. Most cancers 19, R187–R204 (2012).
Karthaus, W. R. et al. Regenerative potential of prostate luminal cells revealed by single-cell evaluation. Science 368, 497–505 (2020).
Chang, S. S. et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Most cancers Res. 5, 2674–2681 (1999).
Conway, R. E. et al. Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. Angiogenesis 19, 487–500 (2016).
Pandit-Taskar, N. et al. Indium 111-labeled J591 anti-PSMA antibody for vascular focused imaging in progressive stable tumors. EJNMMI Res. 5, 13 (2015).
Tagawa, S. T. et al. Section 1/2 examine of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate most cancers. Most cancers 125, 2561–2569 (2019).
Ruggiero, A. et al. Focusing on the interior epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J. Nucl. Med. 52, 1608–1615 (2011).
Eder, M. et al. 68Ga-complex lipophilicity and the concentrating on property of a urea-based PSMA inhibitor for PET imaging. Bioconjug. Chem. 23, 688–697 (2012).
Ganguly, T. et al. A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate most cancers. Nucl. Med. Biol. 42, 780–787 (2015).
Rowe, S. P. et al. Potential analysis of PSMA-targeted 18F-DCFPyL PET/CT in males with biochemical failure after radical prostatectomy for prostate most cancers. J. Nucl. Med. 61, 58–61 (2020).
Kuten, J. et al. Head-to-head comparability of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate most cancers utilizing histopathology and immunohistochemical evaluation as reference-standard. J. Nucl. Med. 61, 527–532 (2020).
Cardinale, J. et al. Procedures for the GMP-compliant manufacturing and high quality management of [18F]PSMA-1007: a subsequent era radiofluorinated tracer for the detection of prostate most cancers. Prescription drugs 10, 77 (2017).
Youn, S. et al. Carborane-containing urea-based inhibitors of glutamate carboxypeptidase II: synthesis and structural characterization. Bioorg. Med. Chem. Lett. 25, 5232–5236 (2015).
Pavlicek, J., Ptacek, J. & Barinka, C. Glutamate carboxypeptidase II: an summary of structural research and their significance for structure-based drug design and deciphering the response mechanism of the enzyme. Curr. Med. Chem. 19, 1300–1309 (2012).
Machulkin, A. E. et al. Small-molecule PSMA ligands. Present state, SAR and views. J. Drug. Goal. 24, 679–693 (2016).
Barinka, C. et al. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J. Med. Chem. 51, 7737–7743 (2008).
Wu, L. Y. et al. The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg. Med. Chem. 15, 7434–7443 (2007).
Novakova, Z. et al. Unprecedented binding mode of hydroxamate-based inhibitors of glutamate carboxypeptidase II: structural characterization and organic exercise. J. Med. Chem. 59, 4539–4550 (2016).
Lucaroni, L. et al. Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics. Eur. J. Nucl. Med. Mol. Imaging 50, 957–961 (2023).
Bidkar, A. P. et al. Therapy of prostate most cancers with CD46-targeted 225Ac alpha particle radioimmunotherapy. Clin. Most cancers Res. 29, 1916–1928 (2023).
Lee, Z., Heston, W. D., Wang, X. & Basilion, J. P. GCP III will not be the “off-target” for urea-based PSMA ligands. Eur. J. Nucl. Med. Mol. Imaging 50, 2944–2946 (2023).
Heynickx, N., Segers, C., Coolkens, A., Baatout, S. & Vermeulen, Ok. Characterization of non-specific uptake and retention mechanisms of [177Lu]Lu-PSMA-617 within the salivary glands. Prescription drugs 16, 692 (2023).
Heynickx, N., Herrmann, Ok., Vermeulen, Ok., Baatout, S. & Aerts, A. The salivary glands as a dose limiting organ of PSMA-targeted radionuclide remedy: a assessment of the teachings learnt up to now. Nucl. Med. Biol. 98, 30–39 (2021).
Emmett, L. et al. The PRIMARY rating: utilizing intraprostatic 68Ga-PSMA PET/CT patterns to optimize prostate most cancers prognosis. J. Nucl. Med. 63, 1644–1650 (2022).
Wolff, A. C. et al. Suggestions for human epidermal progress issue receptor 2 testing in breast most cancers: American Society of Scientific Oncology/School of American Pathologists medical apply guideline replace. J. Clin. Oncol. 31, 3997–4013 (2013).
Paschalis, A. et al. Prostate-specific membrane antigen heterogeneity and DNA restore defects in prostate most cancers. Eur. Urol. 76, 469–478 (2019).
Kuo, P. H., Benson, T., Messmann, R. & Groaning, M. Why we did what we did: PSMA PET/CT choice standards for the VISION trial. J. Nucl. Med. 63, 816–818 (2022).
Seifert, R. et al. Second model of the prostate most cancers molecular imaging standardized analysis framework together with response analysis for medical trials (PROMISE V2). Eur. Urol. 83, 405–412 (2023).
Eiber, M. et al. Prostate most cancers molecular imaging standardized analysis (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J. Nucl. Med. 59, 469–478 (2018).
Saha, G. B. Physics and Radiobiology of Nuclear Drugs (Springer Science & Enterprise Media, 2012).
Calais, J. et al. Security of PSMA-targeted molecular radioligand remedy with 177Lu-PSMA-617: outcomes from the potential multicenter part 2 trial RESIST-PC (NCT03042312). J. Nucl. Med. 62, 1447–1456 (2021).
Arnfield, E. G. et al. Scientific insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective analysis. Eur. J. Nucl. Med. Mol. Imaging 48, 4495–4507 (2021).
Chen, M. Y. et al. Solitary rib lesions displaying prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68Ga-PSMA-11 positron emission tomography scans for males with prostate most cancers: benign or malignant? BJU Int. 126, 396–401 (2020).
Le Wen, C. et al. Components predicting metastatic illness in 68Ga-PSMA-11 PET-positive osseous lesions in prostate most cancers. J. Nucl. Med. 61, 1779 (2020).
Tim, E. P. et al. Predicting outcomes of indeterminate bone lesions on 18F-DCFPyL PSMA PET/CT scans within the setting of high-risk major or recurrent prostate most cancers. J. Nucl. Med. 64, 395 (2023).
Guner, L. A. et al. Enhancing PSMA PET/CT imaging of prostate most cancers: investigating the affect of a number of time level analysis, diuretic administration, cribriform sample, and intraductal carcinoma. Ann. Nucl. Med. 37, 618–628 (2023).
Present, Ok. et al. Investigating PSMA-targeted radioligand remedy efficacy as a operate of mobile PSMA ranges and intratumoral PSMA heterogeneity. Clin. Most cancers Res. 26, 2946–2955 (2020).
Gafita, A. et al. Nomograms to foretell outcomes after 177Lu-PSMA remedy in males with metastatic castration-resistant prostate most cancers: a world, multicentre, retrospective examine. Lancet Oncol. 22, 1115–1125 (2021).
Thang, S. P. et al. Poor outcomes for sufferers with metastatic castration-resistant prostate most cancers with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand remedy. Eur. Urol. Oncol. 2, 670–676 (2019).
Violet, J. et al. Lengthy-term follow-up and outcomes of retreatment in an expanded 50-patient single-center part II potential trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate most cancers. J. Nucl. Med. 61, 857–865 (2020).
Alizadeh, A. A. et al. Towards understanding and exploiting tumor heterogeneity. Nat. Med. 21, 846–853 (2015).
Bedard, P. L., Hansen, A. R., Ratain, M. J. & Siu, L. L. Tumour heterogeneity within the clinic. Nature 501, 355–364 (2013).
Henry, G. H. et al. A mobile anatomy of the conventional grownup human prostate and prostatic urethra. Cell Rep. 25, 3530–3542.e5 (2018).
Stylianou, N. et al. A molecular portrait of epithelial-mesenchymal plasticity in prostate most cancers related to medical consequence. Oncogene 38, 913–934 (2019).
Lin, D. et al. Excessive constancy patient-derived xenografts for accelerating prostate most cancers discovery and drug growth. Most cancers Res. 74, 1272–1283 (2014).
Staniszewska, M. et al. Enzalutamide enhances PSMA expression of PSMA-low prostate most cancers. Int. J. Mol. Sci. 22, 7431 (2021).
Bakht, M. Ok. et al. Affect of androgen deprivation remedy on the uptake of PSMA-targeted brokers: rising alternatives and challenges. Nucl. Med. Mol. Imaging 51, 202–211 (2017).
Meller, B. et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate most cancers cells as a goal for diagnostics and remedy. EJNMMI Res. 5, 66 (2015).
Evans, M. J. et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc. Natl Acad. Sci. USA 108, 9578–9582 (2011).
Kashyap, A. et al. Quantification of tumor heterogeneity: from knowledge acquisition to metric era. Developments Biotechnol. 40, 647–676 (2022).
Assadi, M. et al. Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in sufferers with metastatic castration-resistant prostate most cancers handled with 177Lu-PSMA. Entrance. Oncol. 12, 1066926 (2022).
Lückerath, Ok. et al. Detection threshold and reproducibility of 68Ga-PSMA11 PET/CT in a mouse mannequin of prostate most cancers. J. Nucl. Med. 59, 1392–1397 (2018).
Nguyen, H. M. et al. LuCaP prostate most cancers patient-derived xenografts mirror the molecular heterogeneity of superior illness and function fashions for evaluating most cancers therapeutics. Prostate 77, 654–671 (2017).
Nyquist, M. D. et al. Mixed TP53 and RB1 loss promotes prostate most cancers resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 31, 107669 (2020).
Lee, J. Ok. et al. Systemic surfaceome profiling identifies goal antigens for immune-based remedy in subtypes of superior prostate most cancers. Proc. Natl Acad. Sci. USA 115, E4473–E4482 (2018).
Olivier, P. et al. Section III examine of 18F-PSMA-1007 versus 18F-fluorocholine PET/CT for localization of prostate most cancers biochemical recurrence: a potential, randomized, crossover multicenter examine. J. Nucl. Med. 64, 579–585 (2023).
Morgan, R., Wermuth, D., Molina, E. & Perraillon, M. Utilization and price of radium-223 dichloride (Xofigo®) for therapy of metastatic castration-resistant prostate most cancers (mCRPR) within the U.S. Medicare inhabitants. J. Nucl. Med. 62, 1309–1309 (2021).
Hoving, H. et al. Early 18F-FDHT PET/CT as a predictor of therapy response in mCRPC handled with enzalutamide. J. Clin. Oncol. 37, 232–232 (2019).
Puca, L. et al. Delta-like protein 3 expression and therapeutic concentrating on in neuroendocrine prostate most cancers. Sci. Transl. Med. 11, eaav0891 (2019).
O’Donoghue, J. A. et al. Pharmacokinetics and biodistribution of a [89Zr]Zr-DFO-MSTP2109A anti-STEAP1 antibody in metastatic castration-resistant prostate most cancers sufferers. Mol. Pharm. 16, 3083–3090 (2019).
Bhatia, V. et al. Focusing on superior prostate most cancers with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat. Commun. 14, 2041 (2023).
Kesch, C. et al. Excessive fibroblast-activation-protein expression in castration-resistant prostate most cancers helps using FAPI-molecular theranostics. Eur. J. Nucl. Med. Mol. Imaging 49, 385–389 (2021).
O’Keefe, D. S. et al. Mapping, genomic group and promoter evaluation of the human prostate-specific membrane antigen gene. Biochim. Biophys. Acta 1443, 113–127 (1998).
Afshar-Oromieh, A. et al. Influence of long-term androgen deprivation remedy on PSMA ligand PET/CT in sufferers with castration-sensitive prostate most cancers. Eur. J. Nucl. Med. Mol. Imaging 45, 2045–2054 (2018).
Unterrainer, L. et al. Early adjustments of PSMA PET sign after initiation of androgen receptor signaling inhibitors in mCRPC: a world multicenter retrospective examine. J. Clin. Oncol. 41, 5063–5063 (2023).
Tagawa, S. T. et al. PSMAddition: a part 3 trial to match therapy with 177Lu-PSMA-617 plus normal of care (SoC) and SoC alone in sufferers with metastatic hormone-sensitive prostate most cancers. J. Clin. Oncol. 41, TPS5116–TPS5116 (2023).
Emmett, L. et al. [177Lu]Lu-PSMA-617 plus enzalutamide in sufferers with metastatic castration-resistant prostate most cancers (ENZA-p): an open-label, multicentre, randomised, part 2 trial. Lancet Oncol. 25, 563–571 (2024).
Baca, S. C. et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate most cancers. Nat. Commun. 12, 1979 (2021).
McMullin, R. P. et al. A FOXA1-binding enhancer regulates Hoxb13 expression within the prostate gland. Proc. Natl Acad. Sci. USA 107, 98–103 (2010).
Watt, F. et al. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 73, 243–254 (2001).
Giambartolomei, C. et al. H3K27ac HiChIP in prostate cell strains identifies danger genes for prostate most cancers susceptibility. Am. J. Hum. Genet. 108, 2284–2300 (2021).
Seifert, R. et al. Evaluation of PSMA expression and consequence in sufferers with superior prostate most cancers receiving 177Lu-PSMA-617 radioligand remedy. Theranostics 10, 7812–7820 (2020).
Hindié, E. Predicting outcomes after 177Lu-PSMA remedy in castration-resistant prostate most cancers. Lancet Oncol. 22, e425 (2021).
Wang, Z. et al. Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment. Cell Metab. 35, 1209–1226.e1213 (2023).
Xue, R. et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 612, 141–147 (2022).
Schulte, M. L. et al. Pharmacological blockade of ASCT2-dependent glutamine transport results in antitumor efficacy in preclinical fashions. Nat. Med. 24, 194–202 (2018).
Wang, Q. et al. Focusing on amino acid transport in metastatic castration-resistant prostate most cancers: results on cell cycle, cell progress, and tumor growth. J. Natl Most cancers Inst. 105, 1463–1473 (2013).
Chen, F., Han, Y. & Kang, Y. Bone marrow niches within the regulation of bone metastasis. Br. J. Most cancers 124, 1912–1920 (2021).
Uwe, H., Frederik, G., Alfred, M. & Clemens, Ok. The way forward for radioligand remedy: α, β, or each? J. Nucl. Med. 58, 1017 (2017).
Kostos, L. et al. AlphaBet: mixture of radium-223 and [17 7Lu]Lu-PSMA-I&T in males with metastatic castration-resistant prostate most cancers (medical trial protocol). Entrance. Med. 9, 1059122 (2022).
Rajasekaran, S. A. et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol. Biol. Cell 14, 4835–4845 (2003).
Ghosh, A. & Heston, W. D. Tumor goal prostate particular membrane antigen (PSMA) and its regulation in prostate most cancers. J. Cell Biochem. 91, 528–539 (2004).
Liu, H. et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Most cancers Res. 58, 4055–4060 (1998).
Anilkumar, G. et al. Affiliation of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for concentrating on to tumor vasculature. Microvasc. Res. 72, 54–61 (2006).
Goodman et al. Interplay of prostate particular membrane antigen with clathrin and the adaptor protein complex-2. Int. J. Oncol. 31, 1199–1203 (2007).
Schmidt, S. et al. Discriminatory function of detergent-resistant membranes within the dimerization and endocytosis of prostate-specific membrane antigen. PLoS ONE 8, e66193 (2013).
Anilkumar, G. et al. Prostate-specific membrane antigen affiliation with filamin A modulates its internalization and NAALADase exercise. Most cancers Res. 63, 2645–2648 (2003).
Christiansen, J. J. et al. N-glycosylation and microtubule integrity are concerned in apical concentrating on of prostate-specific membrane antigen: implications for immunotherapy. Mol. Most cancers Ther. 4, 704–714 (2005).
Oudard, S. et al. Cabazitaxel versus docetaxel as first-line remedy for sufferers with metastatic castration-resistant prostate most cancers: a randomized part III trial — FIRSTANA. J. Clin. Oncol. 35, 3189–3197 (2017).
Kondev, F. G. Nuclear knowledge sheets for A=177. Nucl. Knowledge Sheets 159, 1–412 (2019).
Jain, A. Ok., Raut, R. & Tuli, J. Ok. Nuclear knowledge sheets for A = 225. Nucl. Knowledge Sheets 110, 1409–1472 (2009).
Kratochwil, C. et al. Focused α-therapy of metastatic castration-resistant prostate most cancers with 225Ac-PSMA-617: dosimetry estimate and empiric dose discovering. J. Nucl. Med. 58, 1624–1631 (2017).
Enger, S. A., Hartman, T., Carlsson, J. & Lundqvist, H. Cross-fire doses from β-emitting radionuclides in focused radiotherapy. A theoretical examine primarily based on experimentally measured tumor traits. Phys. Med. Biol. 53, 1909 (2008).
McDevitt, M. R., Sgouros, G. & Sofou, S. Focused and nontargeted α-particle therapies. Annu. Rev. Biomed. Eng. 20, 73–93 (2018).
He, Y. et al. Focusing on signaling pathways in prostate most cancers: mechanisms and medical trials. Sign. Transduct. Goal. Ther. 7, 198 (2022).
Enger, S. A., Hartman, T., Carlsson, J. & Lundqvist, H. Cross-fire doses from β-emitting radionuclides in focused radiotherapy. A theoretical examine primarily based on experimentally measured tumor traits. Phys. Med. Biol. 53, 1909–1920 (2008).
Azzam, E. I., De Toledo, S. M., Spitz, D. R. & Little, J. B. Oxidative metabolism modulates sign transduction and micronucleus formation in bystander cells from α-particle-irradiated regular human fibroblast cultures. Most cancers Res. 62, 5436–5442 (2002).
Marie, B. et al. Radiation-induced biologic bystander impact elicited in vitro by focused radiopharmaceuticals labeled with α-, β-, and auger electron-emitting radionuclides. J. Nucl. Med. 47, 1007 (2006).
Bodei, L. et al. The joint IAEA, EANM, and SNMMI sensible steering on peptide receptor radionuclide remedy (PRRNT) in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 40, 800–816 (2013).
Sheehan, B. et al. Prostate-specific membrane antigen expression and response to DNA damaging brokers in prostate most cancers. Clin. Most cancers Res. 28, 3104–3115 (2022).
Salas-Ramirez, M. et al. Radiation-induced double-strand breaks by inner ex vivo irradiation of lymphocytes: validation of a Monte Carlo simulation mannequin utilizing GATE and Geant4-DNA. Z. Med. Phys. https://doi.org/10.1016/j.zemedi.2023.07.007 (2023).
Khreish, F. et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem remedy of metastatic castration-resistant prostate most cancers: pilot expertise. Eur. J. Nucl. Med. Mol. Imaging 47, 721–728 (2020).
Müller, C. et al. Terbium-161 for PSMA-targeted radionuclide remedy of prostate most cancers. Eur. J. Nucl. Med. Mol. Imaging 46, 1919–1930 (2019).
Vlachostergios, P. J. et al. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate most cancers. Prostate 81, 279–285 (2021).
Derlin, T. et al. PSMA-heterogeneity in metastatic castration-resistant prostate most cancers: circulating tumor cells, metastatic tumor burden, and response to focused radioligand remedy. Prostate 83, 1076–1088 (2023).
Vanwelkenhuyzen, J. et al. AR and PI3K genomic profiling of cell-free DNA can establish poor responders to lutetium-177-PSMA amongst sufferers with metastatic castration-resistant prostate most cancers. Eur. Urol. Open. Sci. 53, 63–66 (2023).
Wang, C.-B. et al. Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate most cancers on preliminary biopsy. Clin. Transl. Oncol. 25, 758–767 (2023).
Harmon, S. A. et al. A potential comparability of 18F-sodium fluoride PET/CT and PSMA-targeted 18F-DCFBC PET/CT in metastatic prostate most cancers. J. Nucl. Med. 59, 1665–1671 (2018).
Regula, N. et al. Comparability of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate most cancers relapse. Sci. Rep. 10, 4993 (2020).
Shiiba, M. et al. Analysis of major prostate most cancers utilizing 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann. Nucl. Med. 26, 138–145 (2012).
Zoppolo, F. et al. 11C-SAM: radiosynthesis and preliminary organic research as a possible agent for prostate most cancers prognosis. J. Nucl. Med. 57, 2700–2700 (2016).
Mori, H. et al. Imaging somatostatin receptor exercise in neuroendocrine-differentiated prostate most cancers. Intern. Med. 57, 3123–3128 (2018).
Korsen, J. A. et al. Delta-like ligand 3 — focused radioimmunotherapy for neuroendocrine prostate most cancers. Proc. Natl Acad. Sci. USA 119, e2203820119 (2022).
Kratochwil, C. et al. 68Ga-FAPI PET/CT: tracer uptake in 28 completely different sorts of most cancers. J. Nucl. Med. 60, 801–805 (2019).
Bakht, M. M. Ok. Molecular imaging targets in prostate cancers with neuroendocrine gene signature. Thesis, Univ. Windsor (Canada) https://scholar.uwindsor.ca/etd/8170 (2019).
Uhlen et al. Tissue-based map of the human proteome. Science https://doi.org/10.1126/science.1260419 (2015).
